Arginine Glutamate

Summary

Arginine Glutamate (CHEMBL2104514) is a phase-3 clinical-stage small molecule (ATC A05BA01).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A05BA01
• Chemistry: 321.33 Da · C11H23N5O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104514
Name	Arginine Glutamate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	165268
ATC	A05BA01
Molecular formula	C11H23N5O6
Molecular weight	321.33
InChIKey	RVEWUBJVAHOGKA-WOYAITHZSA-N

SMILES: C(C[C@@H](C(=O)O)N)CN=C(N)N.C(CC(=O)O)[C@@H](C(=O)O)N

IUPAC name: (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2S)-2-aminopentanedioic acid

Also known as: Arginine glutamate, L-arginine l-glutamate (1:1), L-arginine l-glutamate hydrate, Modumate, NSC-122009, ARGININE GLUTAMATE

Patent coverage: 350 distinct patent families (1,162 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,155 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).